Investigating protein levels in kidney transplant patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with focal segmental glomerulosclerosis (FSGS) who are at high risk for developing proteinuria after kidney transplantation. It will analyze serum specimens and kidney transplant specimens before and after reperfusion to identify defects that lead to the recurrence of proteinuria. The study will also review medical records for urine protein levels, blood creatinine, and kidney biopsy results, as well as the characteristics of the fluid used to flush the kidney prior to transplant.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Kidney transplant recipients
* Pediatric males and females up to the age of 25 years old.

Exclusion Criteria:

* Transplant recipients other than kidney

Where it's running

• University of Miami Miller School of Medicine Transplant Clinic
  Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: George Burke, M.D. — University of Miami
• Study coordinator: George Burke, M.D.
• Email: gburke@med.miami.edu
• Phone: 305-355-5111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines

  This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.

  Recruiting at 2 sites St. James's Hospital, Ireland · Dublin and 1 other locations · NCT07561957

• Sparsentan for high-grade proteinuria linked to VEGF inhibitors

  This pilot study tests whether sparsentan can reduce severe proteinuria in adults with cancer who are being treated with VEGF signaling pathway inhibitors.

  Recruiting Phase 1 Brigham and Women's Hospital · Boston, Massachusetts · NCT07224776

• Nefecon (budesonide) plus ambrisentan for IgA nephropathy with proteinuria

  This test will see if combining Nefecon (a gut‑targeted budesonide) with ambrisentan can reduce urine protein and slow kidney decline in adults with IgA nephropathy who have at least 0.5 g of protein in a 24‑hour urine collection.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07030894

• Effects of Amiloride on Chronic Kidney Disease Progression

  This study is testing if the medication amiloride can help people with chronic kidney disease by protecting their kidneys and reducing protein in their urine without changing their blood pressure.

  Recruiting Phase 2 Odense University Hospital · Odense · NCT06923709

• Registry and biobank for resistant nephrotic syndrome treatment responses

  This study is collecting information from patients with resistant nephrotic syndrome to see how different treatments work and to help find better options for the future.

  Recruiting Medical University of Vienna · Vienna · NCT06162546

• Long-term safety of Finerenone for children with chronic kidney disease

  This study is testing the long-term safety of a medication called Finerenone in children and young adults with chronic kidney disease to see how it works when used with other common treatments.

  Recruiting at 23 sites Phase 3 Bayer · Phoenix, Arizona and 150 other locations · NCT05457283

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.